Navigation Links
European Society for Medical Oncology (ESMO) Presents Data from the,Clinical Trial of MediGene's Cancer-Killing Virus in Press,Conference

* Presentation of efficacy trends from ongoing phase I/II trial of oncolytic HSV * Poster selected by ESMO for presentation in press conference

MARTINSRIED, Germany, June 29, 2007.--The biotech company MediGene AG (Frankfurt, Prime Standard: MDG) announces that a case report from the ongoing clinical trial of MediGene's cancer killing virus will be presented in a press conference held by the European Society for Medical Oncology. Out of more than 300 posters accepted for the conference, only five were chosen for presentation in the press conference.

The event will take place on Friday, July 6, at 12:30 MEST at the ESMO conference in Lugano, Switzerland (ECLU). Dr. Axel Mescheder, Head of Clinical Research and Development at MediGene, will present the data in the press conference as well as in a poster presentation during the conference.

The phase I/II trial of NV1020 for the treatment of liver metastases of colorectal cancer is being conducted at seven leading cancer centers in the US. In September 2006, MediGene announced positive safety and efficacy data from an interim analysis of this study. The poster presented at the ESMO conference shows efficacy data in a case study for the first time.

Dr. Ulrich Delvos, Chief Operating Officer of MediGene, comments. "We are delighted and proud that the European Society for Medical Oncology has decided to present a case study from our trial in a press conference. Considering the number of studies presented on Europe's largest cancer congress, this emphasizes the innovation and the potential of this approach to fight cancer."

Journalists interested in joining the press conference please contact media@esmo.org

This press release contains forward-looking statements that involve risks and uncertainties. The forward-looking statements contained herein represent the judgmen t of MediGene as of the date of this release. These forward-looking statements are no guarantees for future performance, and the forward-looking events discussed in this press release may not occur. MediGene disclaims any intent or obligation to update any of these forward-looking statements. MediGeneTM is a trademarks of MediGene AG

- ends -

MediGene AG is a publicly quoted (Frankfurt: Prime Standard: MDG) biotechnology company located in Martinsried/Munich, Germany, with subsidiaries in Oxford, UK and San Diego, USA. MediGene is the first German biotech company with a drug on the market. A second drug has been approved by the FDA. A third drug was recently inlicensed to market this drug in Europe. In addition, several drug candidates are currently in clinical development. MediGene also possesses innovative platform technologies.

Contact MediGene AG: Email:

investor@medigene.com

Fax: ++49 - 89 - 85 65 - 2920 Julia Hofmann/Dr. Georg Dönges, Public Relations Tel.: ++49 - 89 - 85 65 - 3317 Dr. Michael Nettersheim, Investor Relations Tel.: ++49 - 89 - 85 65 - 2946



'"/>




Related medicine technology :

1. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
2. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
3. DOR BioPharma Announces Issuance of European Patent for Its Oral Multivalent Botulinum Toxin Vaccine BT-VACC
4. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
5. Malvern initiates European user group meetings for chemical imaging
6. PARI Pharma Presents Study Results of Sinus Delivery and Inhaled Liposomal Ciclosporin A at European Cystic Fibrosis Conference
7. Targeted Genetics Reports Inflammatory Arthritis Clinical Data at European Rheumatology Conference
8. Can-Fite Proceeds with Development of Third Drug; Progress in Development of CF502 Will Be Presented at the Annual European Congress of Rheumatology
9. Inspire Announces Presentations at Two European Scientific Conferences
10. Sunesis Pharmaceuticals Reports Positive Data From Studies of Two Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of the European Hematology Association
11. Archimedes Pharma Presents Positive Efficacy and Safety Data on Nasalfent at European Association for Palliative Care Congress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... , Feb. 23, 2017 Non-alcoholic ... on the various drugs being developed for ... all the drugs that are in various ... The pipeline focuses on novel pharmacologic drugs ... stem cell therapies, recombinant proteins and RNA-based ...
(Date:2/24/2017)... -- Xynomic Pharmaceuticals, Inc., an oncology drug research and ... exclusive worldwide rights to develop, manufacture and commercialize ... hematological and solid tumors. To date ... clinical trials of Abexinostat in US, EU and ... completed, demonstrating that Abexinostat is clinically active in ...
(Date:2/23/2017)... Research and Markets has announced the addition of the ... report to their offering. ... The latest research Autism Spectrum Disorder Drugs Price Analysis ... the global Autism Spectrum Disorder market. The research answers the ... drugs marketed for Autism Spectrum Disorder and their clinical attributes? How ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... February 24, 2017 , ... HealthPostures, expert ... Core benefits and advantages built into the home office sit stand solution are ... feel. Ability to gain the benefits embedded in the TaskMate Go are available ...
(Date:2/24/2017)... ... February 24, 2017 , ... Dr. Ronald E. Hawkins, vice ... appointment of Peter A. Bell, DO, MBA, HPF, FACOEP-dist., FACEP, as the new ... 10. Dr. Bell comes to Liberty from the Ohio University Heritage College of ...
(Date:2/24/2017)... ... ... The narrative in “ Signal 8: An Australian Paramedic’s Story ” (published by ... Schanssema describes the tragedies he saw, as well as his struggles with grief and ... unsure of the career path he wanted to take, found fulfillment in a career ...
(Date:2/24/2017)... ... ... Indiana Fiber Network (IFN) President and CEO Kelly C. Dyer recently announced ... the Chairman of the Management Committee when IFN was originally formed in 2002 where ... investor/owners and development of the business plan. He became the first paid employee ...
(Date:2/23/2017)... ... February 23, 2017 , ... Thinksport, the most award-winning ... Gran Fondo of Marin. For the second year in a row, cyclists will ... , “We are thrilled to provide our safe, non-toxic sunscreen to over 2,000 ...
Breaking Medicine News(10 mins):